Ibrutinib Plus BR/R-CHOP in Previously Treated Patients With Follicular or Marginal Zone Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 3 SELENE Study: Ibrutinib Plus BR/R-CHOP in Previously Treated Patients with Follicular or Marginal Zone Lymphoma
Blood Adv 2023 Sep 18;[EPub Ahead of Print], LJ Nastoupil, G Hess, MA Pavlovsky, I Danielewicz, JA Freeman, A Martin Garcia-Sancho, V Glazunova, AA Grigg, JZ Hou, A Janssens, SJ Kim, Z Masliak, P McKay, F Merli, W Munakata, H Nagai, M Özcan, M Preis, T Wang, M Rowe, M Tamegnon, R Qin, T Henninger, M Curtis, DB Caces, C Thieblemont, GA SallesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.